Oct 10, 2023 BXCL701 / KEYTRUDA® in Small Cell Neuroendocrine Prostate Cancer Jun 29, 2023 Acute Treatment of Agitation in Alzheimer’s Disease: TRANQUILITY II Summary May 25, 2023 SERENITY III Part 1 Topline Results May 08, 2023 BioXcel Therapeutics Corporate Presentation Mar 02, 2023 Novel Treatment for Agitation in Neuropsychiatric Conditions Feb 21, 2023 BXCL701 KOL Day Presentation Feb 13, 2023 BXCL701 Full Data Results From Phase 2 Trial in Rare, Aggressive Form of Prostate Cancer—SCNC Jan 11, 2023 41th Annual J.P. Morgan Healthcare Conference Presentation Oct 18, 2022 IGALMI Commercial Day Presentation Apr 06, 2022 IGALMI™ Approval Presentation Sep 23, 2021 R&D Day Mar 03, 2021 Phase 1b/2 TRANQUILITY Trial – Program Update Jul 20, 2020 SERENITY I & II Phase 3 Trials Topline Results
Feb 13, 2023 BXCL701 Full Data Results From Phase 2 Trial in Rare, Aggressive Form of Prostate Cancer—SCNC
